Mizuho Downgrades FibroGen to Neutral on 'Higher Risk And Uncertainty'
April 07, 2021 at 10:44 AM EDT
Mizuho analyst Difei Yang downgraded FibroGen to Neutral from Buy with a price target of $29, down from $72.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|